PE20240922A1 - Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos - Google Patents

Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos

Info

Publication number
PE20240922A1
PE20240922A1 PE2023003023A PE2023003023A PE20240922A1 PE 20240922 A1 PE20240922 A1 PE 20240922A1 PE 2023003023 A PE2023003023 A PE 2023003023A PE 2023003023 A PE2023003023 A PE 2023003023A PE 20240922 A1 PE20240922 A1 PE 20240922A1
Authority
PE
Peru
Prior art keywords
treatment
regimes
vegf antagonist
eye disorders
extended high
Prior art date
Application number
PE2023003023A
Other languages
English (en)
Spanish (es)
Inventor
Robert L Vitti
Alyson J Berliner
Karen Chu
Friedrich Asmus
Silva Leal Sergio Casimiro Da
Thomas Eissing
Kay D Rittenhouse
Original Assignee
Regeneron Pharma
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Bayer Healthcare Llc filed Critical Regeneron Pharma
Publication of PE20240922A1 publication Critical patent/PE20240922A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PE2023003023A 2021-05-17 2022-05-16 Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos PE20240922A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163189541P 2021-05-17 2021-05-17
US202163235398P 2021-08-20 2021-08-20
US202263297420P 2022-01-07 2022-01-07
US202263306315P 2022-02-03 2022-02-03
PCT/US2022/029462 WO2022245739A1 (en) 2021-05-17 2022-05-16 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Publications (1)

Publication Number Publication Date
PE20240922A1 true PE20240922A1 (es) 2024-04-30

Family

ID=81975181

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023003023A PE20240922A1 (es) 2021-05-17 2022-05-16 Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos

Country Status (23)

Country Link
US (1) US20230302085A1 (https=)
EP (2) EP4647125A3 (https=)
JP (1) JP2024519629A (https=)
KR (1) KR20240008821A (https=)
AU (2) AU2022275786C1 (https=)
BR (1) BR112023023002A2 (https=)
CA (1) CA3190663A1 (https=)
CL (3) CL2023003396A1 (https=)
DK (1) DK4185318T3 (https=)
ES (1) ES3041647T3 (https=)
FI (1) FI4185318T3 (https=)
HR (1) HRP20251282T8 (https=)
IL (1) IL308505A (https=)
JO (1) JOP20230283A1 (https=)
LT (1) LT4185318T (https=)
MX (1) MX2023013554A (https=)
PE (1) PE20240922A1 (https=)
PL (1) PL4185318T3 (https=)
PT (1) PT4185318T (https=)
RS (1) RS67369B1 (https=)
SI (1) SI4185318T1 (https=)
TW (1) TW202313095A (https=)
WO (1) WO2022245739A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
IL315347A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
IL315374A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) * 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
US20260055171A1 (en) 2024-06-11 2026-02-26 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR20190049934A (ko) * 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
CA3010862A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
HUE059827T2 (hu) * 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
CN117138171A (zh) 2017-12-13 2023-12-01 里珍纳龙药品有限公司 用于精确剂量输送的装置和方法
DK4364724T3 (da) * 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US20220306732A1 (en) * 2019-09-12 2022-09-29 Lupin Limited Modified dosing of vegf inhibitors for ophthalmic use

Also Published As

Publication number Publication date
KR20240008821A (ko) 2024-01-19
BR112023023002A2 (pt) 2024-01-23
FI4185318T3 (fi) 2025-10-13
AU2022275786A8 (en) 2023-04-20
AU2022275786B2 (en) 2025-06-05
EP4185318B1 (en) 2025-09-03
JOP20230283A1 (ar) 2023-11-06
HRP20251282T8 (hr) 2025-12-19
MX2023013554A (es) 2023-11-29
PT4185318T (pt) 2025-09-29
CL2025001269A1 (es) 2025-08-22
EP4647125A3 (en) 2026-01-28
EP4185318A1 (en) 2023-05-31
PL4185318T3 (pl) 2026-01-12
WO2022245739A1 (en) 2022-11-24
LT4185318T (lt) 2025-11-10
DK4185318T3 (da) 2025-09-29
SI4185318T1 (sl) 2025-10-30
HRP20251282T1 (hr) 2025-12-05
CA3190663A1 (en) 2022-11-24
IL308505A (en) 2024-01-01
EP4647125A2 (en) 2025-11-12
JP2024519629A (ja) 2024-05-21
RS67369B1 (sr) 2025-11-28
AU2022275786C1 (en) 2025-12-11
CL2023003396A1 (es) 2024-06-07
ES3041647T3 (en) 2025-11-13
AU2025226774A1 (en) 2025-09-25
TW202313095A (zh) 2023-04-01
CL2024002972A1 (es) 2025-01-24
US20230302085A1 (en) 2023-09-28
AU2022275786A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
PE20240922A1 (es) Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos
MX2024011079A (es) Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos
MX2017011459A (es) Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
MX2020005166A (es) Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.
AR092860A1 (es) Formulacion oftalmica y metodo para mejorar la presbicia
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
CL2024002718A1 (es) Regímenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogénicos.
AR082077A1 (es) Compuestos para el tratamiento de trastornos y enfermedades del segmento posterior
MX2016005680A (es) Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea.
MX2019015150A (es) Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión.
CL2021000329A1 (es) Compuestos útiles en terapia del vih
MX2024015576A (es) Tratamiento para migra?as
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
MX2021015654A (es) Antagonista del receptor 2 de prostaglandina e2 (ep2).
EA202190966A1 (ru) Пролекарства антагонистов cgrp
MX2020008456A (es) Uso de tradipitant para tratar la cinetosis.
WO2021048779A3 (en) Modified dosing of vegf inhibitors for ophthalmic use
MX391657B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
ECSP21010874A (es) Piridopirimidinas como inhibidores del receptor de histamina h4
MX2019002607A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
IL325345A (en) Extended high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
MX2022004155A (es) Compuestos antagonistas del receptor 4 de prostaglandina e2 (ep4).
MX394840B (es) Nuevos metodos para el tratamiento de la esclerosis multiple.
CA3297204A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders